Semantic review is behind discovery. Evidence and Pulse may be incomplete until the backlog is cleared.
2 material first-party/frontier/open-problem candidate(s) have waited more than 6 hours for semantic review.
EVIDENCE REGISTER
A chronological register of published signals. Source class, verification state, evidence quality and relevance remain visible before interpretation.
Nature reports AGENTEX, a robotic cell-free workflow that prototypes alternative genetic codes using engineered ribosomes and tRNAs; the study demonstrates compressed codes, non-standard amino-acid incorporation and reassignment of up to three codons, while remaining in vitro rather than a demonstrated living-organism implementation.
Moderna and Merck reported that individualized mRNA neoantigen therapy intismeran autogene plus pembrolizumab met the primary recurrence-free-survival endpoint and the key distant-metastasis-free-survival endpoint in the 1,137-patient Phase 3 INTerpath-001 study after resection of high-risk stage IIB-IV melanoma. Full effect sizes and detailed data have not yet been released.
FDA granted accelerated approval to Genglycos (pariglasgene brecaparvovec-opnr), a one-time AAV8 gene therapy delivering a functional G6PC gene to the liver for patients age 8+ with GSDIa. In a randomized placebo-controlled study, treated patients had a statistically significant 31% mean reduction in daily cornstarch intake; confirmatory trials are still required.
GenBio AI introduced AIDO Cell, a multiscale simulator integrating multimodal biological data into a shared world model intended to simulate cellular responses and support therapeutic design. The company reports literature-based validation and says prospective wet-lab validation of novel predictions is underway.